References
- Sharma SV, Bell DW, Settleman J and Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7, 169-181 https://doi.org/10.1038/nrc2088
- Ciardiello F and Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7, 2958-2970
- Tam IY, Chung LP, Suen WS et al (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12, 1647-1653 https://doi.org/10.1158/1078-0432.CCR-05-1981
- Riely GJ, Politi KA, Miller VA and Pao W (2006) Update on epidermal growth factor receptor mutations in nonsmall cell lung cancer. Clin Cancer Res 12, 7232-7241 https://doi.org/10.1158/1078-0432.CCR-06-0658
- Paez J, Janne P, Lee J et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 https://doi.org/10.1126/science.1099314
- Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73 https://doi.org/10.1371/journal.pmed.0020073
- Dass CR, Choong PF and Khachigian LM (2008) DNAzyme technology and cancer therapy: cleave and let die. Mol Cancer Ther 7, 243-251
- Kim JE, Yoon S, Choi BR et al (2013) Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinibresistant BCR-ABL leukemic cells. Leukemia 27, 1650-1658 https://doi.org/10.1038/leu.2013.60
- Santoro S and Joyce G (1997) A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A 94, 4262-4266 https://doi.org/10.1073/pnas.94.9.4262
- Khachigian L (2000) Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J Clin Invest 106, 1189-1195 https://doi.org/10.1172/JCI11620
- Silverman SK (2008) Catalytic DNA (deoxyribozymes) for synthetic applications-current abilities and future prospects. Chem Commun (Camb), 3467-3485
- Appaiahgari MB and Vrati S (2007) DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain. Mol Ther 15, 1593-1599 https://doi.org/10.1038/sj.mt.6300231
- Bessis N, GarciaCozar FJ and Boissier MC (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11 Suppl 1, S10-17 https://doi.org/10.1038/sj.gt.3302364
- Akira S, Uematsu S and Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124, 783-801 https://doi.org/10.1016/j.cell.2006.02.015
- Aderem A and Ulevitch R (2000) Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787 https://doi.org/10.1038/35021228
- Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas R and Wagner H (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32, 1958-1968 https://doi.org/10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U
- Wagner EF and Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537-549 https://doi.org/10.1038/nrc2694
-
Lee KJ, Kim YK, Krupa M et al (2016) Crotamine stimulates phagocytic activity by inducing nitric oxide and TNF-
$\alpha$ via p38 and$ NF{\kappa}$ -B signaling in RAW 264.7 macrophages. BMB Rep 49, 185-190 https://doi.org/10.5483/BMBRep.2016.49.3.271 - Kim YH, Girardi M, Duvic M et al (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 63, 975-983 https://doi.org/10.1016/j.jaad.2009.12.052
- da Rosa MR, Falcao AS, Fuzii HT et al (2014) EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma. Tumour Biol 35, 11107-11120 https://doi.org/10.1007/s13277-014-2401-3
- Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5, 471-484 https://doi.org/10.1038/nrd2059
- Droemann D, Albrecht D, Gerdes J et al (2005) Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 6, 1 https://doi.org/10.1186/1465-9921-6-1
- Latz E, Verma A, Visintin A et al (2007) Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 8, 772-779 https://doi.org/10.1038/ni1479
-
Tsujimura H, Tamura T, Kong HJ et al (2004) Toll-Like Receptor 9 Signaling Activates NF-
${\kappa}B$ through IFN Regulatory Factor-8/IFN Consensus Sequence Binding Protein in Dendritic Cells. J Immunol 172, 6820-6827 https://doi.org/10.4049/jimmunol.172.11.6820